Clinical Trial

Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the change in glycated hemoglobin (HbA1c) levels from baseline to 24 weeks after the combination therapy of cofrogliptin, metformin and SGLT2i (dapagliflozin) in type 2 diabetes mellitus (T2DM) patients with poor control of glucose level by metformin and SGLT2i combination therapy.
Trial Details
NCT Number NCT07019012
Lead Sponsor Huazhong University of Science and Technology
Collaborators: Renmin Hospital of Wuhan University, Wuhan Central Hospital, Taihe Hospital, Xiangyang No.1 People's Hospital, The First Affiliated Hospital of Nanchang University
Conditions T2DM
Enrollment 170 participants
Start Date 2025-07-30
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-13